Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunocore Holdings (IMCR) Current Assets (2019 - 2025)

Immunocore Holdings' Current Assets history spans 4 years, with the latest figure at -$62.1 million for Q4 2025.

  • For Q4 2025, Current Assets fell 106.68% year-over-year to -$62.1 million; the TTM value through Sep 2025 reached $1.0 billion, up 1.68%, while the annual FY2025 figure was -$62.1 million, 106.68% down from the prior year.
  • Current Assets for Q4 2025 was -$62.1 million at Immunocore Holdings, down from $1.0 billion in the prior quarter.
  • Across five years, Current Assets topped out at $1.0 billion in Q3 2025 and bottomed at -$62.1 million in Q4 2025.
  • The 4-year median for Current Assets is $939.2 million (2024), against an average of $773.3 million.
  • The largest annual shift saw Current Assets soared 75.84% in 2024 before it plummeted 106.68% in 2025.
  • A 4-year view of Current Assets shows it stood at $474.0 million in 2022, then grew by 11.57% to $528.8 million in 2023, then surged by 75.84% to $929.9 million in 2024, then tumbled by 106.68% to -$62.1 million in 2025.
  • Per Business Quant, the three most recent readings for IMCR's Current Assets are -$62.1 million (Q4 2025), $1.0 billion (Q3 2025), and $1.0 billion (Q2 2025).